Roche - GRIPonMASH

A healthier future. That’s what drives Roche to innovate. To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.

Within the Innovative Health Initiative (IHI) GRIPonMASH, Roche is particularly interested in exploring the clinical utility of blood based biomarkers for the assessment of liver fibrosis in MASLD/MASH patients and HCC in high-risk patients. Their goal is to improve tools for non-invasive assessment of liver fibrosis in MASLD/MASH in primary care populations which is urgently needed.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, Efpia, EuropaBio, MedTech Europe, Vaccines Europe and Mercodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV.

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.